AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2017
Sep 5, 2017
31580_dirs_2017-09-05_a639b8cf-c272-4ee8-b650-2b955dedf0c3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2017-09-01
Reporting Person: Biller Scott (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-09-01 | Common stock | M | 2146 | $9.05 | Acquired | 8410 | Direct |
| 2017-09-01 | Common stock | S | 2146 | $61.99 | Disposed | 6264 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-09-01 | Stock option (right to buy) | $9.05 | M | 2146 | Disposed | 2023-04-30 | Common stock (2146) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common stock | 25470 | Indirect |
Footnotes
F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $61.31 to $62.51. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4: Shares held by a spousal lifetime access trust, of which the reporting person's wife is trustee.
F5: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.